

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/995,911
		Filing Date	November 28, 2001
		First Name Inventor	Mazess et al.
		Group Art Unit	1617
		Examiner Name	Theodore J. Criares
		Attorney Docket Number	017620-9335

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
-------------------	-----------------------------	---	---------------------------------------


BA	4,160,803	Potts	07/10/79
BB	4,717,721	DeLuca et al.	01/25/88
BC	4,902,481	Clark et al.	02/20/90
BD	5,141,719	Fernwood et al.	08/25/92
BE	5,205,989	Aysta	04/27/93
BF	5,219,528	Clark	06/15/93
BG	5,232,836	Bouillon et al.	08/03/93
BH	5,264,184	Aysta et al.	11/23/93
BI	5,264,618	Felgner et al.	11/23/93
BJ	5,334,740	Takahashi et al.	08/02/94
BK	5,338,532	Tomalia et al.	08/16/94
BL	5,417,923	Bojanic et al.	05/23/95
BM	5,527,524	Tomalia et al.	06/18/96
BN	5,554,386	Groman et al.	09/10/96
BO	5,597,575	Breitbarth	01/28/97
BP	5,614,513	Knutson et al.	03/25/97
BQ	5,637,742	Valles et al.	06/10/97
BR	5,661,025	Szoka, Jr. et al.	08/26/97
BS	5,691,328	Peterson et al.	11/25/97

Examiner Signature	<i>TJ Criares</i>	Date Considered	6/21/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Patent Work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/995,911
				Filing Date	November 28, 2001
				First Named Inventor	Mazess et al.
				Group Art Unit	1617
				Examiner Name	Theodore J. Criares
Sheet	2	of	2	Attorney Docket Number	017620-9335

RECEIVED  
DEC 02 2003  
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.


PC	CS	Packman, K. et al. "Combination Treatment of MCF-7 Xenografts with the Vitamin D <sub>3</sub> Analog EB1089 and Antiestrogens," (Vitamin D Endocrine Workshop, Nashville, TN May 27-June 1, 2000) pp. 511-514.
	CT	Ravid, A. et al., "1,25-Dihydroxyvitamin D <sub>3</sub> Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage," <i>Cancer Research</i> , (February 15, 1999) 59:862-867.
	CU	Siwinska, A. et al. "Potentiation of the Antiproliferative Effect <i>in Vitro</i> of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D," <i>Anticancer Research</i> , (2001) 21:1925-1929.
	CV	Slapak, C. et al., "Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol," <i>Amer. J. Hematology</i> , (1992) 41:178-183.
	CW	Song, X.D. et al., "Bryostatin-1 and 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Synergistically Stimulate the Differentiation of NB4 Acute Promyelocytic Leukemia Cells," <i>Leukemia</i> , (1999) 13:275-281.
	CX	Studzinski, G. et al., "Potentiation by 1- $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea," <i>J. National Cancer Inst.</i> , (April 1986) 76:4:641-648.
	CY	Suzuki, Y. et al., "The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell - The Combination with the Growth Factor Interaction Inhibitor (Suramin)," <i>Acta Urologica</i> (1993) 12:1215-1220, (Abstract).
	CZ	Swami, S. et al. "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells," <i>Clinical Cancer Research</i> , (Aug. 2000) 6:3371-3379.
	DA	Torres, R. et al., "Etoposide Stimulates 1,25-Dihydroxyvitamin D <sub>3</sub> Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells, <i>Molecular and Cellular Biochemistry</i> , (2000) 208:157-162.
	DB	Wang, Q. et al., "1,25-Dihydroxyvitamin D <sub>3</sub> and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death," <i>Cancer Research</i> , (April 2000) 60:2040-2048.
	DC	Wang, X. et al., "Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D <sub>3</sub> -Induced Differentiation of Human Leukemia HL60 Cells," <i>Experimental Cell Research</i> , (2000) 258:425-437.
✓	DD	Yu, W. et al., "Enhancement of 1,25-Dihydroxyvitamin D <sub>3</sub> -Mediated Antitumor Activity with Dexamethasone," <i>J. National Cancer Inst.</i> , (January 1998) 90:2:134-141.

Q:\client\017620\9335\B0265973.1

Examiner Signature		Date Considered	6/21/02
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	09/995,911		
		<b>Filing Date</b>	November 28, 2001		
		<b>First Name Inventor</b>	Mazess et al.		
		<b>Group Art Unit</b>	1617		
		<b>Examiner Name</b>	Theodore J. Criares		
<b>Sheet</b>	2	<b>of</b>	1	<b>Attorney Docket Number</b>	017620-9335

RECEIVED  
DEC 2 2003  
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

BT	5,739,271	Sridhar et al.	04/14/98
BU	5,795,882	Bishop et al.	08/18/98
BV	5,798,345	Knutson et al.	08/25/98
BW	6,503,893	Bishop et al.	01/07/03
BX	6,521,608	Henner et al.	02/18/03
BY	6,537,982	Bishop et al.	03/25/03
BZ	6,538,037	Bishop et al.	03/25/03

FOREIGN PATENT DOCUMENTS							
Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
CA	Japan	5320127	Nisshin Flour Milling Co.	09/29/93			
CB	Japan	6025039	Kurary Co. Ltd.	02/01/94			
CC	Japan	62000033	General Hospital	10/15/86			
CD	PCT	WO 93/07883	ISIS Pharmaceuticals	04/29/93			


Q:\client\017620\9335\B0265972.1

<b>Examiner Signature</b>		<b>Date Considered</b>	6/21/04
---------------------------	--	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form PTO/SB/08B				<b>Complete if Known</b>	
				Application Number	09/995,911
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Filing Date	November 28, 2001
				First Named Inventor	Mazess et al.
				Group Art Unit	1617
				Examiner Name	Theodore J. Criares
				Attorney Docket Number	017620-9335
Sheet	1	of	2		

RECEIVED  
DEC 02 2003  
TECH CENTER 1600/2900**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--	---

CE	Beer, T. et al., "Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer," <i>Journal of Clinical Oncology</i> , (Jan. 2003) 21:1:123-128.
CF	Brazsek, I. et al. "Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1 $\alpha$ ,25 Dihydroxyvitamin D <sub>3</sub> , and Prednisone," 16:4:259-264 (Abstract). <i>Rec'd Date</i>
CG	Carter, Stephen K. et al. <i>Chemotherapy of Cancer</i> 2 <sup>nd</sup> Ed. (1981) 362-365.
CH	Cho, Y.L. et al., "Combined Effects of 1,25-Dihydroxyvitamin D <sub>3</sub> and Platinum Drugs on the Growth of MCF-7 Cells," <i>Cancer Research</i> , (June 1991) 51:2848-2853.
CI	Defacque, H. et al., "Different Combinations of Retinoids and Vitamin D <sub>3</sub> Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines," <i>J. Pharmacology and Experimental Therapeutics</i> , (1994) 271:193-199.
CJ	Endo, K. et al., "Effect of Combination Treatment with Vitamin D Analog (OCT) and a Bisphosphonate (AHPBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia," <i>Journal of Bone and Mineral Research</i> , (1998) 13:9:1378-1383.
CK	Hershberger, P. et al. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i> and Accelerates Paclitaxel-induced Apoptosis," <i>Clinical Cancer Research</i> , (April 2001) 7:1043-1051.
CL	Johnson, C. et al., "Vitamin D-related Therapies in Prostate Cancer," <i>Cancer and Metastasis Review</i> 21, (2002) pp. 147-158.
CM	<i>Journal of Bone and Mineral Research</i> , (1994) 9:5:607-614.
CN	Kim, S. et al., "Potentiation of 1,25-Dihydroxyvitamin D <sub>3</sub> -Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone," <i>Biochem. Pharmacology</i> , (2002) 64:1233-1242.
CO	Londowski, J.M. et al., "Biological Activity of the C-1, C-3, C-25, $\beta$ -D-Glucopyranosides of 1,25-Dihydroxyvitamin D <sub>3</sub> ," <i>J. Pharmacology Expr. Ther.</i> , (1986) 237:3:837-840.
CP	Mathias, C.J. et al., "Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate," <i>J. Nucl. Med.</i> (1996), 37(6):1003-1008.
CQ	Moffatt, K. et al., "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines," <i>Clinical Cancer Research</i> , (March 1999) 5:695-703.
CR	Muindi, J. et al., "Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase 1 Trial of Calcitriol and Paclitaxel," <i>Clinical Pharmacology &amp; Therapeutics</i> , (Dec. 2002) pp. 648-659.

Examiner Signature	<i>TJ Criares</i>	Date Considered	6/21/01
-----------------------	-------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620/9324

SERIAL NO.: 09/891,814

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Bishop et al

(Use several sheets if necessary)

FILING DATE: June 26, 2001

GROUP: 1614



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[Signature]</i>	A	4,554,106	Nov 19, 1985	DeLuca et al			
	B	4,670,190	Jun 2, 1987	Hesse et al			
	C	5,486,636	Jan 23, 1996	DeLuca et al			
	D	5,488,120	Jan 30, 1996	Knutson et al			
	E	6,025,346	Feb 15, 2000	Knutson et al			
	F	6,087,350	Jul 11, 2000	Johnson et al			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>[Signature]</i>	G	WO 99/49870	Oct 7, 1999	PCT			
	H	WO 01/64251	Sep 7, 2001	PCT			
	I	WO 99/16451	Apr 8, 1999	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

6/21/04

EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 017620/9324

SERIAL NO.: 09/891,814

APPLICANT: Bishop et al

FILING DATE: June 26, 2001

GROUP: 1614

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

COPY OF PAPERS  
ORIGINALLY FILED



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>pc</i>	4,698,328	Oct 6, 1987	Neer, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>pc</i>	WO 92/05130	Apr 2, 1992	PCT			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

6/26/04

EXAMINER: Initial If citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.


Substitute for form 1449B/PTO			<b>Complete if Known</b>		
			Application Number	09/995,911	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Filing Date	November 28, 2001	
			First Named Inventor	Mazess et al.	
			Group Art Unit	1617	
			Examiner Name	Theodore J. Criares	
			Attorney Docket Number	017620-9335	
Sheet	1	of	2		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.	
DE	Albert, D.M. et al., "Verhoeff's Query: Is Vitamin D Effective Against Retinoblastoma?" <i>Arch. Ophthalmol</i> (1988) 106:536-540.		
DF	Cohen, S.M. et al., "Further Studies of the Effect of Vitamin D on Retinoblastoma," <i>Arch. Ophthalmol</i> (1988) 106:541-543.		
DG	Colston, K.W. et al., "Possible Role for Vitamin D in Controlling Breast Cancer Cell Proliferation," <i>Lancet</i> (Jan. 28, 1989) 188-191.		
DH	Colston, K. et al., "1,25-Dihydroxyvitamin D <sub>3</sub> and Malignant Melanoma: The Presence of Receptors and Inhibition of Cell Growth in Culture," <i>Endocrinology</i> (1981) 108:3:1083-1086.		
DI	Colston, K.W. et al., "Effects of Synthetic Vitamin D Analogues on Breast Cancer Cell Proliferation <i>In Vivo</i> and <i>In Vitro</i> ," <i>Biochemical Pharmacology</i> (1992) 44:4:693-702.		
DJ	Cross, H.S. et al., "Antiproliferative Effect of 1,25-Dihydroxyvitamin D <sub>3</sub> and its Analogs on Human Colon Adenocarcinoma Cells (CACO-2): Influence of Extracellular Calcium," <i>Biochem. Biophysical Res. Comm.</i> (1991) 179:1:57-62.		
DK	Cross, H.S. et al., "Growth Inhibition of Human Colon Adenocarcinoma-Derived Caco-2 Cells by 1,25-Dihydroxyvitamin D <sub>3</sub> and Two Synthetic Analogs: Relation to <i>In Vitro</i> Hypercalcemic Potential," <i>Archives of Pharmacology</i> , (1993) 347:105-110.		
DL	Etsuko, A. et al. "Differentiation of Mouse Myeloid Leukemia Cells Induced by 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> ," <i>Proc. Natl. Acad. Sci.</i> (1981) 78:8:4990-4994.		
DM	Hedlund, T.E. et al., "Vitamin D Receptor Expression is Required for Growth Modulation by 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> in the Human Prostatic Carcinoma Cell Line ALVA-31," <i>J. Steroid Biochem. Molec. Biol.</i> (1996) 58:3:277-288.		
DN	Hedlund, T.E. et al., "Stable Expression of the Nuclear Vitamin D Receptor in the Human Prostatic Carcinoma Cell Line JCA-1: Evidence that the Antiproliferative Effects of 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> are Mediated Exclusively Through the Genomic Signaling Pathway," <i>Endocrinology</i> (1996) 137:5:1554-1561.		
DO	Higashimoto, Y. et al., "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> and All-Trans-Retinoic Acid Inhibit the Growth of a Lung Cancer Cell Line," <i>Anticancer Research</i> (1996) 16:2653-2660.		
DP	Honma, Y. et al., "1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> and 1 $\alpha$ -Hydroxyvitamin D <sub>3</sub> Prolong Survival Time of Mice Inoculated with Myeloid Leukemia Cells," <i>Cell Biology</i> (1983) 80:201-204.		
DQ	McElwain, M.C. et al., "Antiproliferative Effects <i>In Vitro</i> and <i>In Vivo</i> of 1,25-Dihydroxyvitamin D <sub>3</sub> and a Vitamin D <sub>3</sub> Analog in a Squamous Cell Carcinoma Model System," <i>Molecular and Cellular Differentiation</i> , (1995) 3(1):31-50.		
Examiner Signature		Date Considered	6/21/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PT

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/995,911
Filing Date	November 28, 2001
First Named Inventor	Mazess et al.
Group Art Unit	1617
Examiner Name	Theodore J. Criares
Attorney Docket Number	017620-9335

Sheet 2 of 2

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**Examiner  
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

DR	Mehta, R.G. et al., "Prevention of Preneoplastic Mammary Lesion Development by a Novel Vitamin D Analogue, 1 $\alpha$ -Hydroxyvitamin D <sub>3</sub> ," <i>J. National Cancer Inst.</i> (1997) 89:3:212-218.
DS	Peehl, D.M., et al., "Antiproliferative Effects of 1,25-Dihydroxyvitamin D <sub>3</sub> on Primary Cultures of Human Prostatic Cells," <i>Cancer Research</i> (1994) 54:805-810.
DT	Schwartz, G.G. et al., "Human Prostate Cancer Cells: Inhibition of Proliferation by Vitamin D Analogs," <i>Anticancer Research</i> (1994) 14:1077-1082.
DU	Schwartz, G.G. et al., "1,25-Dihydroxy-16-Ene-23-Yne-Vitamin D <sub>3</sub> and Prostate Cancer Cell Proliferation <i>In Vivo</i> ," <i>Urology</i> (1995) 46:3:365-369.
DV	Shabahang, M. et al., "The Effect of 1,25-Dihydroxyvitamin D <sub>3</sub> on the Growth of Soft-Tissue Sarcoma Cells as Mediated by the Vitamin D Receptor," <i>Annals of Surgical Oncology</i> (1996) 3:2:144-149.
DW	Skowronski, R.J. et al., "Actions of Vitamin D <sub>3</sub> Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D <sub>3</sub> ," <i>Endocrinology</i> (1995) 136:1:20-26.
DX	Skowronski, R.J. et al., "Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D <sub>3</sub> Receptors and Actions in Human Prostate Cancer Cell Lines," <i>Endocrinology</i> (1993) 132:5:1952-1960.
DY	Tokuuni, Y. "Correlation Between the Concentration of 1,25 $\alpha$ Dihydroxyvitamin D <sub>3</sub> Receptors and Growth Inhibition, and Differentiation of Human Osteosarcoma Cells Induced by Vitamin D <sub>3</sub> ," <i>J. Jpn. Orthop. Assoc.</i> (1995) 69:181-190.
DZ	Yabushita, H. et al., "Vitamin D Receptor in Endometrial Carcinoma and the Differentiation-Inducing Effect of 1,25-Dihydroxyvitamin D <sub>3</sub> on Endometrial Carcinoma Cell Lines," <i>J. Obstet. Gynaecol. Res.</i> (1996) 22:6:529-539.
EA	Zhou, J. et al., "Novel Vitamin D Analogs that Modulate Leukemic Cell Growth and Differentiation with Little Effect on Either Intestinal Calcium Absorption or Bone Calcium Mobilization," <i>Blood</i> (1989) 74:1:82-93.
EB	Zhuang, S-H, et al., "Vitamin D Receptor Content and Transcriptional Activity do not Fully Predict Antiproliferative Effects of Vitamin D in Human Prostate Cancer Cell Lines," <i>Molecular and Cellular Endocrinology</i> (1997) 126:83-90.
EC	Zugmaier, G., et al., "Growth-Inhibitory Effects of Vitamin D Analogues and Retinoids on Human Pancreatic Cancer Cells," <i>British Journal of Cancer</i> (1996) 73:1341-1346.
ED	<i>Proceedings of the American Association for Cancer Research</i> (1997) 38:456.

Q:\client\017620\9335\B0265973.1

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.